Mutations in the Juxtamembrane Domain of c-KIT Are Associated with Higher Grade Mast Cell Tumors in Dogs

Veterinary Pathology

Volumn 39, Issue 5, 2002, Pages 529-535

  Zemke, D ^a   Yamini, B ^b   Yuzbasiyan Gurkan, V ^a,b  

^a Michigan State University ^*  (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

c kit Receptor; DNA; dogs; mastocytoma; mutation; polymerase chain reaction; sequence analysis; single nucleotide polymorphism

Indexed keywords

DNA; STEM CELL FACTOR RECEPTOR;

AMINO ACID SEQUENCE; ANIMAL; ANIMAL DISEASE; ARTICLE; CHEMISTRY; DOG; DOG DISEASE; GENETIC PREDISPOSITION; GENETICS; MASTOCYTOMA; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; POLYMERASE CHAIN REACTION; SKIN TUMOR;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; DNA, NEOPLASM; DOG DISEASES; DOGS; GENETIC PREDISPOSITION TO DISEASE; MASTOCYTOMA; MOLECULAR SEQUENCE DATA; MUTATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-KIT; SKIN NEOPLASMS;

EID: 0036730274     PISSN: 03009858     EISSN: 15444221     Source Type: Journal    
DOI: 10.1354/vp.39-5-529     Document Type: Article

References (21)

1. Banerjee SK, Makdisi WF, Weston AP, Mitchell SM, Campbell DR: Microwave-based DNA extraction from paraffin-embedded tissue for PCR amplification. Bio- Techniques 18: 768–773, 1995
2. Bhattacharyya A, Lilley DMJ: The contrasting structures of mismatched DNA sequences containing looped-out bases (bulges) and multiple mismatches (bubbles). Nucleic Acids Res 17: 6821–6840, 1989
3. Broudy VC: Stem cell factor and hematopoiesis. Blood 90: 1345–1364, 1997
4. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295: 139–145, 2000
5. Cohen D, Reif JS, Brodey RS, Keiser H: Epidemiological analysis of the most prevalent sites and types of canine neoplasia observed in a veterinary hospital. Cancer Res 34: 2859–2868, 1974
6. Druker BJ, Lydon NB: Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 105: 3–7, 2000
7. Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, Sugahara H, Butterfield JH, Ashman LK, Kanayama Y, Matsuzawa Y, Kitamura Y, Kanakura Y: Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 92: 1736–1744, 1993
8. Kitayama H, Kanakura Y, Furitsu T, Tsujimura T, Oritani K, Ikeda H, Sugahara H, Mitsui H, Kanayama Y, Kitamura Y, Matsuzawa Y: Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood 85: 790–798, 1995
9. London CA, Galli SJ, Yuuki T, Hu Z, Helfand SC, Geissler EN: Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp Hematol 27: 689–697, 1999
10. Ma Y, Longley BJ, Wang X, Blount JL, Langley K, Caughey GH: Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms. J Invest Dermatol 112: 165–170, 1999
11. Patnaik AK, Ehler WJ, MacEwen EG: Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Vet Pathol 21: 469–474, 1984
12. Priester WA: Skin tumors in domestic animals. Data from 12 United States and Canadian colleges of veterinary medicine. J Natl Cancer Inst 50: 457–466, 1973
13. Qiu F, Ray P, Brown K, Barker PE, Jhanwar S, Ruddle FH, Besmer P: Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family-oncogenic activation of v-kit involves deletion of extracellular domain and C terminus. Eur Mol Biol Organ J 7: 1003–1011, 1988
14. Serve H, Yee NS, Stella G, Sepp-Lorenzino L, Tan JC, Besmer P: Differential roles of PI3-kinase and Kit tyrosine 821 in Kit receptor-mediated proliferation, survival and cell adhesion in mast cells. Eur Mol Biol Organ J 14: 473–483, 1995
15. Tsujimura T, Furitsu T, Morimoto M, Isozaki K, Nomura S, Matsuzawa Y, Kitamura Y, Kanakura Y: Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation. Blood 83: 2619–2626, 1994
16. Tsujimura T, Furitsu T, Morimoto M, Kanayama Y, Nomura S, Matsuzawa Y, Kitamura Y, Kanakura Y: Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3. Int Arch Allergy Immunol 106: 377–385, 1995
17. Tsujimura T, Morimoto M, Hashimoto K, Moriyama Y, Kitayama H, Matsuzawa Y, Kitamura Y, Kanakura Y: Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain. Blood 87: 273–283, 1996
18. Vail DM: Mast cell tumors. In: Small Animal Clinical Oncology, ed. Withrow SJ, MacEwen EG, 2nd ed., pp. 192–210. WB Saunders, Philadelphia, PA, 1996
19. Valent P, Spanblöchl E, Sperr WR, Sillaber C, Zsebo KM, Agis H, Strobl H, Geissler K, Bettelheim P, Lechner K: Induction of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture. Blood 80: 2237–2245, 1992
20. Yarden Y, Kuang W, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, Chen E, Schlessinger J, Francke U, Ullrich A: Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. Eur Mol Biol Organ J 6: 3341–3351, 1987
21. Zemke D, Yamini B, Yuzbasiyan-Gurkan V: Characterization of an undifferentiated malignancy as a mast cell tumor using mutation analysis in the proto-oncogene c-KIT. J Vet Diagn Invest 13: 341–345, 2001